Other immune exhaustion markers such as CD39 and TOX, as well as those recently been identified (e.g. TIGIT, TIM‐3, CTLA‐4) and their respective ligands in tumors, can be screened to identify their regulation and how their expression pattern can be modulated to improve tumor‐infiltrating lymphocytes activation in combination with ICB therapies. Here, ENTPD1 is linked to neoplasm.